Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMAB807 vs Prolia in Postmenopausal Osteoporosis (High Fracture Risk)
CTR20202319Phase 3Completed
- Sponsor
- Shanghai Biomabs
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of denosumab in osteoporosis, sponsored by Shanghai Biomabs. Started Nov 2020; status: completed.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on CTR20202319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202319.